Pano/GemBuMel is Safe and Effective in High-Risk or Relapsed/Refractory Myeloma
Yago Nieto, MD, PhD, discusses the findings from a phase 2 trial evaluating treatment with panobinostat, gemcitabine, busulfan, and melphalan for high-risk or relapsed/refractory myeloma.
